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Snake Antivenom: an Essential Medicine – and a Black Box 
Venomous snakebites are regarded as one of the World’s most neglected tropical 
diseases/conditions with up to 2.5 million victims every year1. The best-practice 
treatment is antivenom derived from the blood of large mammals (typically horses or 
sheep) immunized with venom of one or more snake species. The active toxin-
neutralizing components in antivenom are complex mixtures of antibodies (or fragments 
hereof)2. The individual antibodies are adapted by the immune system of the production 
animal to bind specific to parts of each toxin used in the immunization procedure. In 
many cases antivenom is also able to neutralize some – or even all – toxic effects of 
snakebites from related snake species3.  
Proteomics-based studies aiming at quantifying the extent of such cross-protection 
of antivenoms against venoms from related snake species are referred to as 
antivenomics. The current state-of-the-art antivenomics protocol involves affinity 
chromatography of venoms with immobilized antibodies4. Although proven effective in 
clinical applications antivenomics fail to explain how this cross-reactivity is working at 
the molecular level and must be performed for one snake venom-antivenom pair at a 
time.  
Knowledge of interactions between the immunoreactive parts (referred to as 
epitopes) of a toxin or macromolecule in general and the corresponding antibodies is a 
prerequisite to understand and predict neutralization potential of a given antivenom 
against any fully characterized snake venom. Although antivenom to snakebites is a 
more than 120 years old invention1, only little is known about the neutralizing 
antibodies or their epitopes5.  
 
Ideas and Perspectives 
•  Identify linear peptides from snake toxins that can bind antibodies in antivenom using 
custom designed high-density peptide microarray technology6. See figure 1 
•  The microarrays in this study have been designed to contain five technical replicates 
of 93’261 15-mer peptides derived 966 toxins from pit viper snake species (sub-family 
Viperidae). 
•  Localize epitopes in peptide hits 
•  Characterizing important antibody-toxin interactions based on allowed variation of 
epitope 
•  Predict cross-reactivity of antivenoms on a protein family level and thereby expand 
the clinical applications of existing antivenoms to other snake species or suggest 
changes in immunization mixture to improve the medicine 
•  Learning from nature’s preferences for specific epitopes, it will be possible to estimate 
the number of antibodies needed to neutralize the critical toxins for any given snake 
species 
•  In the long run this may result in recombinant immunization mixtures and even lead 
to the first fully recombinant antivenom 
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Figure 1 – Schematic overview of principle in peptide microarray experiments 
#   Sequence                Signal
7   RYIELAVVADHGIFT   0
8    YIELAVVADHGIFTK 207
9     IELAVVADHGIFTKY 225
10     ELAVVADHGIFTKYN 225
11      LAVVADHGIFTKYNS      255
12       AVVADHGIFTKYNSN 255
13        VVADHGIFTKYNSNL 255
14         VADHGIFTKYNSNLN 156
15          ADHGIFTKYNSNLNT 105
16           DHGIFTKYNSNLNTI  12
            ADHGIFTK
#   Sequence                Signal
7   RYIELVVVADHRVFM   0
8    YIELVVVADHRVFMK 120
9     IELVVVADHRVFMKY 138
10     ELVVVADHRVFMKYN 201
11      LVVVADHRVFMKYNS 201
12       VVVADHRVFMKYNSD 156
13        VVADHRVFMKYNSDL 156
14         VADHRVFMKYNSDLN  51
15          ADHRVFMKYNSDLNT  45
16           DHRVFMKYNSDLNTI   0
            ADHRVFMK
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Bothrops asper– Uniprot P83512 
Figure 2 – Signal plots for two snake venom metalloproteinases (SVMP) belonging to the P-I sub-family. 
Peaks in the signal plots result from binding events between consecutive peptides from the protein 
sequence of toxins and antibodies in ICP anti-Bothrops antivenom. Bothrops asper venom was used in 
the immunization procedure and the SVMP in the upper plot is known to represent approx. 30 % of 
the total protein composition in venom from adult specimens7. The SVMP from Crotalus atrox 
displayed the lower plot is not present in the immunization mixture but shares 60 % of the amino acids 
with the B. asper SVMP. The lower plot strongly indicates a cross-neutralization potential of the ICP 
antivenom. 
Result example – Venom Metalloproteinase P-I subfamily 
Figure 3 – Alignment of peptide 7 to 16 of the SVMPs from the signal plots in figure 2 including the 
running median signal score calculated as median of signals from peptide and the nearest neighbors 
on each side. The binding core is highlighted with red squares.   
Figure 4 – Crystal structure of B. asper 
SVMP-PI (PDB entry 2W15). The -helix 
highlighted in red correspond to the binding 
core of one or more antibody from the ICP 
antivenom 
  
